Roche: lung cancer study update

(CercleFinance.com) - Roche announces an update on the SKYSCRAPER-01 phase III study, evaluating tiragolumab plus Tecentriq® (atezolizumab) versus Tecentriq alone in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with elevated PD-L1.


SKYSCRAPER-01 is a global, randomized, double-blind, Phase III study evaluating tiragolumab plus Tecentriq versus Tecentriq alone in 534 patients with previously untreated, unresectable or metastatic locally advanced NSCLC with high PD-L1.

The study did not meet the primary endpoint of overall survival in the final analysis. The overall safety profile observed remained consistent with longer follow-up, and no new safety signals were identified. Detailed data will be presented at a medical meeting in 2025.

Roche constantly reassesses its study programs to determine whether adjustments are necessary for ongoing research needs.

Roche will apply the same principles to this program, with additional data from Phase III studies in different settings and tumor types planned for next year," says the company.

Copyright (c) 2024 CercleFinance.com. All rights reserved.